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Introduction 
Lung cancer is the commonest cause of cancer death worldwide. In the UK a 10 year survival rate of 4.9% remains disappointingly low [1]. Given that most patients with lung cancer are incurable at diagnosis, with survival typically measured in ‘months’ [2], targeting treatments at improved quality of life, extended life or both is the priority [3]. In general, more radical treatment options carry more significant side-effects and a greater patient burden. An informed understanding of the likely outcomes following radical treatments is therefore important for clinicians and patients alike, ahead of treatment plans being made.
Clinical decision making in lung cancer in the UK is informed by national guidelines [4, 5], which are underpinned by an extensive evidence base. However, the lung cancer population is typically elderly and multimorbid  ADDIN EN.CITE [2, 4-6], and such patients are under-represented in clinical trials. Indeed, a recent review of international lung cancer guideline concordance questioned the generalizability of clinical guidelines to ‘real world’ patients [7].
In addition to cancer treatment modality, a number of factors are known to influence prognosis in lung cancer, including disease stage  ADDIN EN.CITE [2, 6, 8, 9], age  ADDIN EN.CITE [2, 6, 8], gender  ADDIN EN.CITE [2, 6], performance status  ADDIN EN.CITE [2, 6, 9, 10], systemic inflammation  ADDIN EN.CITE [10-13], comorbidity  ADDIN EN.CITE [2, 6], muscle wasting  ADDIN EN.CITE [11, 14, 15], and weight loss  ADDIN EN.CITE [8, 15-18]. Cachexia, a complex syndrome encompassing many of these poor prognostic factors (namely weight loss, muscle wasting and systemic inflammation), is responsible for numerous negative patient outcomes in cancer [19]. However, it is not currently assessed or managed in any systematic or consistent way in the lung cancer clinic. 
There is a lack of understanding about which predictive factors relate to early mortality (presumed to be a consequence of anti-cancer treatment) and which to reduced overall survival as a result of progressive cancer. The potential for severe adverse outcomes due to cancer treatment toxicity is well recognised [4, 5] and ‘death within 30 days of systemic anti-cancer treatment’ (SACT) is now a commonly employed proxy for quality of care [20]. Death within the 90 day post-treatment period is of interest in surgical cancer populations [21] and in Scotland lung cancer mortality within 30 or 90 days of the receipt of anti-cancer treatment is a routinely-collected quality performance indicator [22].  
Where evidence does exist around prognostic and predictive factors, assimilating this into clinical decision making can be a challenge. Furthermore, there can be a lack of understanding by some patients that cancer treatment has the potential to do more harm than good. Evidence is needed to inform discussions between lung cancer clinicians and their ‘real world’ patients about the likely benefits and the potential harms of treatment. It is only with this evidence that cancer treatments can be targeted most appropriately. 
The aim of this retrospective cohort study was to identify predictive factors for 30 and 90 day mortality following chemoradiotherapy for lung cancer, and factors that were prognostic for overall survival.




Methods  
All patients diagnosed with lung cancer between 2008 and 2010 in South East Scotland given chemoradiotherapy were included in the retrospective cohort study. National Caldicott approval was granted for the collation of existing patient data.

Population
Individuals diagnosed with lung cancer in South East Scotland between 2008 and 2010 given either concurrent or sequential chemoradiotherapy (CRT) were included. Concurrent CRT is the UK guideline recommended treatment for patients with stage II-III Non-Small Cell Lung Cancer (NSCLC) not suitable for surgery but of good performance status, and for patients with limited Small Cell Lung Cancer (SCLC) whose disease is encompassable in a radiotherapy field and are of good performance status [4, 5]. Sequential CRT is less effective in NSCLC than concurrent treatment [23], though it remains an option for patients unfit for concurrent CRT at diagnosis who respond to chemotherapy [4].

Demographic and clinical information was obtained from the South East Scotland Cancer Audit Network (SCAN) database, including cancer histology and stage [24], Eastern Cooperative Oncology Group Performance Status [25] at diagnosis and details of completed cancer treatments. Date of diagnosis for each patient was taken as the date of their diagnostic computed tomography (CT) scan. Height, weight, weight loss history at diagnosis and details of comorbid illness were obtained from clinical notes. Routine diagnostic CT scans were utilised for body composition analysis (see ‘CT body composition analysis’ section), and disease progression following treatment was assessed by comparing diagnostic and follow-up CT scans (see ‘CT evidence of progression’ section). Where patients had died, details of registered causes of death were obtained from the Scottish Health Services, ‘Information Services Division’ (ISD).

Body Mass Index (BMI)
BMI was classified into: underweight (<20), normal weight (20-24.9), overweight (25-29.9) or obese (>30) [15].

Weight loss as a marker of cachexia
Patient-reported weight loss (of any specified or unspecified amount) at diagnosis was recorded, and has previously been shown to be a reliable measure  ADDIN EN.CITE [26, 27]. No attempt to quantify weight loss was made, since this was inconsistently recorded or reported by patients.

CT body composition analysis
Diagnostic CT scans were accessed from the Picture Archiving and Communication System (PACS) and a single cross-sectional image from the fourth thoracic (T4) vertebral level was utilised for body composition analysis  ADDIN EN.CITE [15, 28-32].  Skeletal muscle area (cm2) and muscle attenuation (MA, measured in Hounsfield Units, HU) were derived for each patient by a single trained investigator using Slice-O-Matic V4.3 software (Tomovision, Montreal, Canada)  ADDIN EN.CITE [14, 15, 28, 30, 31]. A HU range of -29 to 150 was used to identify skeletal muscle. Whole body muscle mass (muscularity) was calculated by normalising skeletal muscle area (cm2) for stature (m2), and was reported as skeletal muscle index (SMI). Fatty infiltration of skeletal muscle (myosteatosis) was quantified on the basis of skeletal muscle density and was recorded as muscle attenuation (MA). 

Thresholds for high/low SMI and MA levels using CT-based body composition analysis have been reported for several cancer populations  ADDIN EN.CITE [14, 15, 28, 30, 31, 33, 34] but not specifically in chemoradiotherapy for lung cancer. Given this, optimal stratification (OS) [14, 35] was used  to determine cut-offs for high/low SMI and MA (continuous covariates) in relation to overall survival. The latter was conducted using SAS software, version 9.4 of the SAS System for Windows. Copyright © 2012 SAS Institute Inc. Sex-specific cut-offs are reported for both muscularity and MA, in line with others’ work  ADDIN EN.CITE [15, 28, 31]. 

CT evidence of disease progression
Post-treatment CT scans were examined by a single thoracic radiologist for evidence of disease progression. There are recognised challenges associated with accurately assessing disease recurrence/response after high dose thoracic radiotherapy  ADDIN EN.CITE [36, 37]. Therefore, no attempt was made to quantify disease. Rather, a pragmatic assessment was made, with patients classified as having ‘progressive disease’ or not. The radiologist was blinded to patient outcomes during the review. 
Outcome Measures
Three outcome measures were examined, 30 day, 90 day and overall survival. 30 and 90 day survival were calculated from the last day of receipt of cancer treatment (primary chemoradiotherapy only). Overall survival was calculated from date of diagnosis. 

Statistical analysis 
Data were analysed using SPSS v19 (IBM SPSS Statistics, Ontario, Canada). Simple bivariate associations of categorical variables were analysed using the chi-squared test. The relationships between a continuous and a categorical variable were analysed with the Student’s t-test or Mann-Whitney U for non-parametric data. Continuous variables were examined with Pearson correlation. Multivariable relationships were examined using general linear models (usually logistic regression) to explore the association between clinical and demographic factors and the outcome variables. Cox regression was used to examine the relationship between the explanatory variables and survival. 

Where appropriate, odds ratios (OR) for logistic regression and hazard ratios (HR) for survival are reported. All tests are two-sided, and a significance level of 5% has been assumed.
Results  

Patient characteristics at diagnosis
Demographic and clinical characteristics at diagnosis for all 194 patients who underwent chemoradiotherapy for lung cancer diagnosed in South East Scotland between 2008 and 2010 are outlined in Table 1. The majority of patients had either stage III NSCLC or limited stage SCLC, and were treated with concurrent CRT. 90% of patients had an ECOG PS of 0/1. The mean BMI for both men and women was in the overweight (BMI >25) category, with over half of women and nearly two-thirds of men classified as either overweight or obese. Over half of the patients reported weight loss at diagnosis. Male patients typically had more muscle than females and slightly higher muscle attenuation (MA).

Association between BMI, weight-losing status and body composition
As BMI increased, so did muscularity (r= 0.44, p<0.001), though muscle attenuation fell (r=0.37, p<0.001). See ‘CT body composition analysis’ Methods section for explanation of measures. Patients reporting weight loss at diagnosis had a lower BMI (mean BMI 25.0 versus 27.7, 95% CI of difference (1.23, 4.17), p<0.001) than those who reported no weight loss.  

Chemotherapy completion rates
All 194 patients received some chemotherapy, but 25 patients completed only 1 or 2 cycles (where the intention was 3 or more). Patients completing fewer than 3 cycles of chemotherapy were more likely to be older (67.3 vs 62.3, 95% CI of difference (0.84, 8.85), p=0.02) and to have NSCLC rather than SCLC (94/169 vs 19/25, p=0.054). 

Follow-up CT scans
172/194 patients had CT scans following completion of chemoradiotherapy. The median time to follow-up scan from the last day of treatment was 91 days (IQR 55-111.5). 158/172 CT scans encompassing the required fields were available for specialist radiology review. 29/158 patients had clear evidence of disease progression, either locally (n=5), at a distant site (n=17) or both (n=7).

Survival outcome measures

30 and 90 day survival
22/194 patients (11%) died within 90 days of chemoradiotherapy completion, of whom 4 died within 30 days. There were insufficient deaths within 30 days for meaningful analysis. 10/22 patients’ follow-up CT scans were available for evaluation. Only 2/22 showed clear evidence of disease progression, although the reported primary cause of death for 20/22 patients was ‘lung cancer’.

Univariate analysis of variables associated with death within 90 days of treatment completion is reported in Table 2. Patients with ECOG PS  ≥2, BMI <20 or who reported weight loss were significantly more likely to die within 90 days. On multivariable analysis, only BMI <20 and ECOG PS ≥2 remained independently associated with death within 90 days of CRT completion, see Table 2. Combining these significant variables to create a new variable proved additionally predictive, see Table 3. Patients with either poor ECOG PS, or BMI<20, or both, were significantly more likely to die within 90 days than those in the best prognostic category (ECOG PS 0/1 and BMI ≥20). 

Overall survival
Median overall survival was 19.0 months (95% CI 16.3, 21.7). There was no significant difference in overall survival between those with different cancer type or stage, reflecting the relative homogeneity of the cohort. On univariate analysis, ECOG PS, patient-reported weight loss at diagnosis and low muscle attenuation (MA) were significantly associated with survival, see Table 4. Only MA remained independently associated with survival on multivariable analysis. Median survival for patients with low MA was 15.2 months (95% CI 12.7, 17.7) and for patients with high MA was 23.0 months (95% CI 18.3, 27.8), HR 1.61, p=0.03 (Figure 1). 


Discussion  
Treatment with CRT for lung cancer is lengthy and often burdensome. The expectation for the majority of patients is of significantly extended survival. Current criteria for commencing treatment include disease stage and performance status.  In the present study, 98 % and 89% of patients respectively survived more than 30 and 90 days following completion of CRT thereby suggesting that, for the majority, these criteria are fit for purpose. For the 22/194 (11.3%) patients who died within 90 days, BMI<20 and ECOG PS ≥2 at diagnosis were independent predictors of death. 
Metabolic and functional bankruptcy predicts death within 90 days of treatment completion
The present study population was selectively ‘well’, by virtue of the fact that all were deemed fit to undergo CRT; indeed, >90% of patients were of the best performance status (ECOG 0/1). 18/194 patients who had an ECOG of ≥2 at diagnosis had an OR of death within 90 days of treatment completion of 3.97 (adjusted) compared with their fitter counterparts (ECOG PS 0/1). Poor performance status as measured by ECOG has repeatedly been shown to be associated with reduced survival in lung cancer  ADDIN EN.CITE [9, 10, 18, 38-40]. In a landmark study of weight loss in cancer [17], poor performance status (ECOG ≥2) surpassed weight loss as the major determinant of reduced survival. 
In the present study, 10.0% of patients were underweight by BMI (BMI<20) at diagnosis, a figure comparable with other reported lung cancer series  ADDIN EN.CITE [15, 16, 28]. Patients with low BMI were at increased risk of death within 90 days of CRT completion. Previous studies have shown neo-adjuvant chemotherapy to be associated with significant loss of lean body mass [41] and one explanation for the present findings would be that during CRT those with low BMI may reach a critical level of malnutrition that compromises survival. In a study of >8000 patients with advanced cancer prone to developing cachexia, Martin [16] demonstrated the importance of pre-existing reduced nutritional reserve (low BMI) as an independent adverse prognostic criterion. An earlier study by Martin [15] similarly showed BMI to be the most important determinant of survival. 
Martin [16] has recently coined the concept of ‘metabolic bankruptcy’ as a description of patients with the lowest BMI for whom the outlook is bleak. In the present study, it was arguably both metabolic and functional bankruptcy, with BMI <20 and ECOG ≥2, predicting death within 90 days of treatment completion. It is worthy of note that patients treated with CRT with BMI <20 and ECOG ≥2 identified by this study were deemed fit for treatment, in contrast with other patients with disease that was theoretically treatable but who were not fit for the treatment (not included in this study). Thus, the present study’s findings potentially underestimate the negative effects of low BMI and poor ECOG in predicting early mortality following CRT. Identifying patients in the lung cancer clinic with these risk factors for early death is straightforward, and could usefully inform discussions with patients about the potential risks of proposed cancer treatment.
Gross tumour volume and pre-treatment pulmonary function have previously been shown to be independently prognostic for early mortality following CRT for lung cancer [42]. This earlier study did not include BMI, and ECOG PS was only prognostic on univariate analysis.
Low muscle attenuation (MA), indicative of systemic inflammation, is prognostic for overall survival  
In the present study, low MA (myosteatosis, infiltration of muscle by fat) was independently prognostic for overall survival. Individuals with low MA had a median survival of 15.2 months (95% CI 12.7, 17.7) compared to 23.0 months (95% CI 18.3, 27.8), for those with high MA, p=0.03. Myosteatosis, indexed by low MA on CT scans, is associated with skeletal muscle wasting as part of the cancer cachexia syndrome [43], but may also reflect ageing, obesity or non-malignant disease  ADDIN EN.CITE [31, 44].  In comparison with other studies reporting MA values in lung cancer, the present CRT cohort had relatively high average MA. This could be explained by the earlier disease stage and relative fitness compared to other reported populations  ADDIN EN.CITE [15, 33]. The association between myosteatosis and systemic inflammation (SI) is known  ADDIN EN.CITE [31, 33, 44]. SI is a well-recognised poor prognostic factor in a range of cancer types, with several studies reporting reduced survival in lung cancer patients with active SI  ADDIN EN.CITE [10-13, 45]. The association between low MA and adverse survival in the present study may be due to a number of different processes, including occult disseminated cancer, cachexia and comorbidity.
A history of weight loss at diagnosis has repeatedly been shown to be prognostic in lung cancer  ADDIN EN.CITE [8, 15, 16, 18, 39]. In the present study weight loss was prognostic on univariate but not multivariable analysis, suggesting that its prognostic significance was related to low MA and systemic inflammation. Weight loss as low as 2.4% has been linked with reduced survival [16], in line with the concept of early or ‘pre-cachexia’ [19]. Weight loss during the first three weeks of CRT treatment for lung cancer (before the onset of radiation-induced oesophagitis) has also been shown to be independently prognostic  ADDIN EN.CITE [40]. In a comparable CRT cohort, weight loss on treatment was shown to occur independently of oesophagitis and nutritional intake [46]. It therefore appears likely that cachexia drives weight loss in advance of, alongside and as a direct result of cancer treatment [19]. For the majority of patients in the present study, cachexia would have been apparently invisible, with fewer than 10% of patients underweight by BMI. Therefore, looking beyond an apparently ‘well-nourished’ exterior is needed.
Limitations
The retrospective nature of the present study brings a number of limitations. Outcome measure selection was limited by the availability of routine clinical data from 2008-10. Therefore measures relating to quality of life, causes of hospitalisation, actual causes of death and the incidence and severity of CRT toxicity were not included. Despite a moderately sized cohort (194) who underwent CRT, there were low numbers in some stratified analysis groups. The present study utilised cut-offs of 30 and 90 days following receipt of last cancer treatment to identify early deaths. An alternative approach identifying deaths within 180 days of commencing CRT [42] would remove treatment length as a potential confounder. 

Conclusions
The present study has identified three clinical variables (low performance status, low BMI and low MA) associated with significantly reduced survival (early and late) following CRT for lung cancer.  Further work is needed to validate these findings and to examine the relationship between comorbid illness, frailty and cachexia. Understanding more about actual causes of early death, including the relationship with treatment toxicity, should also be a priority. Patient selection for lung cancer treatment remains an inexact science, but could be improved by better understanding of which patients are most at risk of adverse outcomes following treatment. 
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